Scientists evaluate JNK inhibitors in treating moderate to severe COVID-19 patients

Janus kinase (JNK) inhibitors with antiviral and anti-inflammatory properties have shown promising outcomes in treating symptomatic coronavirus disease 2019 (COVID-19) patients. In a systematic review article published in the journal Cochrane Database of Systematic Reviews, scientists have described the clinical outcomes in hospitalized COVID-19 patients who have been treated with JNK inhibitors together with standard of care.